Le Lézard
Classified in: Health
Subject: PLW

SmartTab Reaches Crucial Milestone with New Patent


DENVER, Jan. 20, 2022 /PRNewswire-PRWeb/ -- The Denver-based startup, SmartTab, continues to revolutionize digital medicine?they successfully obtained a patent for a "wireless communications system integrating electronics into orally ingestible products for controlled release of active ingredients."

Smart Pills for Optimized Drug Delivery

This is yet another major stepping stone for the startup. Over the past three years they've quickly made a name for themselves as a leading innovator in wireless drug delivery systems. The company is engaged in the validation of InjectTabtm to replace the needle and syringe for patients with diabetes and autoimmune diseases. Their additional products, TargetTabtm and MultiTabtm have the potential to transform the lives of people suffering from chronic gastrointestinal problems like Crohn's disease.

To maximize medications' effectiveness and minimize side effects, the drug needs to be targeted to the correct location and at the right time. Modern enteric-coated capsules have advanced oral drug delivery by enabling drugs to dissolve after they have bypassed the acidic stomach environment, yet even these capsules can not travel deep into the colon or offer an indication of whether or not the drug was successfully released at the target location.

Patent Details

The patent (U.S. Patent No. 11224383) has SmartTab poised for clinical studies in May. It entails a consumable capsule with a triaxial coil and electronic circuit which interacts with an external device so that the external device can determine the location of the capsule within the gastrointestinal tract. This system of consumable capsule and external tracking and control device delivers a pharmaceutical agent to a predetermined location in the gastrointestinal tract. The capsule electronics can present a signal indicating release of the pharmaceutical agent.

"The new patent issued and soon-to-be-issued patents demonstrate our commitment to advancing a paradigm shift in patient-centered drug delivery."

-Robert Niichel, Chief Executive Officer of SmartTab

Coming Up

SmartTab is presenting at the Annual Arab Health 2022 Conference 24-27 January 2022 at Dubai World Trade Centre?showcasing Colorado's expertise in novel drug delivery systems to the Middle East and international communities. Additionally, they've launched an equity crowdfunding campaign to support their evolution to become the world's leader in ingestible wireless drug delivery.

Media Contact

Sacha Francois Heppell, SmartTab, +1 (720) 220-4152, [email protected]

Twitter

 

SOURCE SmartTab


These press releases may also interest you

at 14:30
Life-saving Life Imaging Fla., celebrated the grand opening of its newest state-of-the-art facility in Coral Gables, dedicated to the early detection of heart disease and cancer. "We are grateful to Mayor Vince Lago for welcoming us to Coral Gables....

at 12:20
More than 3800 Riders left Exhibition Place in Toronto and another 400 Riders left Niagara Falls in the 17th annual Ride to Conquer Cancer, Canada's largest athletic fundraiser. So far, this year's event has raised $20 million in supporting...

at 09:03
Eli Lilly and Company announced detailed results from SYNERGY-NASH, a phase 2 study of 190 patients, with or without type 2 diabetes, to evaluate the investigational use of tirzepatide in adults with biopsy-proven metabolic dysfunction-associated...

at 09:00
United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, is on the brink of a significant milestone as it approaches its 30,000th global unit installed. This milestone, set to be achieved with the installation of a uMI...

at 08:16
Product: Energy Drink Mixes Issue: Food - Chemical Distribution: National See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

7 jun 2024
Qu Biologics Inc., a Burnaby-based clinical-stage biotechnology company, is pleased to announce that the RESILIENCE Study, a clinical trial evaluating a new immunomodulator designed to strengthen natural immunity among seniors aged 65 or older, is...



News published on and distributed by: